Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
10 December 2009 - 3:51AM
PR Newswire (US)
ANN ARBOR, Mich., Dec. 9 /PRNewswire-FirstCall/ -- Aastrom
Biosciences (NASDAQ:ASTM) announces the following Webcast: What:
Aastrom Biosciences Fiscal Year 2009 Annual Meeting of Shareholders
When: Monday, December 14, 2009 @ 4:00 pm (Eastern) Where:
http://www.investorcalendar.com/IC/CEPage.asp?ID=151462 How: For
live Internet access, simply log on to the web at the link above.
Shareholders and other interested parties will be able to listen to
the entire Annual Meeting of Shareholders. After the business
portion of the meeting, Aastrom will present a corporate slideshow
that will include brief presentations by: 1) Amit N. Patel, M.D.,
M.S., Associate Professor of Surgery at the University of Utah
School of Medicine and National Principal Investigator of the
Company's IMPACT-DCM clinical trial, 2) Anthony J. Comerota, M.D.,
F.A.C.S., F.A.C.C., Director of the Jobst Vascular Center, Adjunct
Professor at the University of Michigan and National Principal
Investigator of the Company's RESTORE-CLI clinical trial, and 3) a
compassionate use patient treated with the Company's Vascular
Repair Cells (VRCs) will share his personal experiences. Only
shareholders in attendance at the meeting will have the opportunity
to participate in the Question & Answer session. Contact:
Investor Relations Department, (734) 930-5777 or If you are unable
to listen to the live webcast, a replay of the meeting will be
archived at http://www.investorcalendar.com/ until March 15, 2010.
About Aastrom Biosciences, Inc. Aastrom is a leader in regenerative
medicine developing autologous cell products for the treatment of
severe, chronic cardiovascular diseases. The Company's proprietary
Tissue Repair Cell (TRC) technology expands the numbers of stem and
early progenitor cells from a small amount of bone marrow collected
from the patient. Bone marrow provides a rich source of diverse
cell populations, is easily accessible and allows Aastrom to
produce a personalized treatment for site-specific delivery to the
patient's diseased tissues. Aastrom has treated more than 350
patients in various clinical trials over 10 years without any
product safety issues. The Company is currently conducting a Phase
II cardiac regeneration clinical trial (the IMPACT-DCM trial) in
patients with dilated cardiomyopathy (DCM - severe chronic heart
failure) and a Phase IIb vascular regeneration clinical trial (the
RESTORE-CLI trial) in patients with critical limb ischemia (CLI -
the most severe form of peripheral arterial disease). Aastrom has
also recently announced that the Company will initiate its U.S.
Phase II clinical trial to evaluate the catheter delivery of CRCs
for the treatment of DCM. http://www.aastrom.com/ DATASOURCE:
Aastrom Biosciences CONTACT: Investor Relations Department,
+1-734-930-5777, Web Site: http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024